Title : Efficacy of lenalidomide in myelodysplastic syndromes.

Pub. Date : 2005 Feb 10

PMID : 15703420






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSIONS: Lenalidomide has hematologic activity in patients with low-risk myelodysplastic syndromes who have no response to erythropoietin or who are unlikely to benefit from conventional therapy. Lenalidomide erythropoietin Homo sapiens